MedTrace Logo

Methylene Blue in Sepsis: A Randomized Controlled Trial

NCT00486174 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2008-05-29

No results posted yet for this study

Summary

The purpose of this study is to investigate whether the addition of Methylene Blue to the standard treatment of septic shock will reduce vasopressor requirements

Conditions

Interventions

DRUG

methylene blue

2.0 mg/kg of Methylene Blue administered every 6 hours (as required) for up to 48 hours.

Sponsors & Collaborators

  • The Physicians' Services Incorporated Foundation

    collaborator OTHER

  • Queen's University

    lead OTHER

Principal Investigators

  • Daniel W Howes, MD · Queen's University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00486174 on ClinicalTrials.gov